Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Hefei
Clinical trial register · China

Clinical Trials in Hefei, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Hefei

896 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Gritgen Therapeutics Co., Ltd.
Early Phase 1
9
Hefei
2027-12-31
Not yet open
Anhui Provincial Hospital
Phase 2
59
Hefei
2027-08-01
Not yet open
Boehringer Ingelheim
Phase 3
1,500
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2027-01-11
Not yet open
Sacituzumab Tirumotecan Plus Toripalimab for Advanced Penile Cancer After Platinum Chemotherapy
NCT07907861Penile Squamous Cell Carcinoma (PSCC), Advanced Penile Cancer, Metastatic Penile Cancer, Locally Advanced Penile Cancer
Anhui Provincial Hospital
Phase 2
31
Hefei
2027-01-01
Not yet open
The Second Hospital of Anhui Medical University
Not applicable
440
Hefei
2027-01
Not yet open
NK521 in the Treatment of Advanced Solid Tumors
NCT07657416Hepatocellular Carcinoma (HCC), Ovarian Cancer, Malignant Ascites
Base Therapeutics (Shanghai) Co., Ltd.
Early Phase 1
18
Hefei
2027-01
Not yet open
The Second Hospital of Anhui Medical University
Not applicable
440
Hefei, Huai'an, Yangzhou
2027-01
Not yet open
Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases
NCT07523282Autoimmune Disease, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc)
DrugHN2302
Shenzhen MagicRNA Biotechnology Co., Ltd
Phase 1
12
Hefei
2026-12-31
Not yet open
Shenzhen MagicRNA Biotechnology Co., Ltd
Phase 1
6
Hefei
2026-12-31
Not yet open
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
76
Chongqing, Guangzhou, Guizhou, Hangzhou, Hefei, Nanjing, Qingdao, Shenzhen
2026-12-25
Not yet open
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
628
Hefei, Nanjing, Shanghai
2026-12-20
Recruiting
Amgen
Phase 3
180
Hefei, Beijing, Chongqing, Fuzhou, Zhengzhou, Wuhan, Nanjing, Suzhou
2026-12-18
Not yet open
Bristol-Myers Squibb
Phase 3
2,380
Hefei, Beijing, Shenzhen, Guangzhou, Shenzhen Shi, Zhengzhou, Shijiazhuang, Yichang Shi
2026-12-16
Not yet open
Boehringer Ingelheim
Phase 3
270
Beijing, Chongqing, Dongguan, Guangzhou, Hefei, Luoyang, Nanchang, Nanjing
2026-12-14
Not yet open
Eli Lilly and Company
Phase 3
2,115
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Jinan
2026-12
Not yet open
Guangdong Second Provincial General Hospital
Not applicable
818
Hefei, Guangzhou
2026-12
Not yet open
Eli Lilly and Company
Phase 3
192
Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Luoyang Shi, Nanchang
2026-12
Not yet open
Lee's Pharmaceutical Limited
Phase 1
36
Hefei
2026-11-30
Not yet open
Shanghai Henlius Biotech
Phase 2/3
1,438
Hefei, Beijing, Chongqing, Nanning, Zunyi, Shijiazhuang, Harbin, Anyang
2026-11-30
Recruiting
The First Affiliated Hospital of Anhui Medical University
Early Phase 1
12
Hefei
2026-11-23
Not yet open
Efficacy of Lipoic Acid on Chronic Ischemic Heart Failure Patients
NCT07725484Heart Failure Due to Coronary Artery Disease
Shanghai Zhongshan Hospital
Phase 3
1,188
Hefei, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Nanjing, Dalian, Xi'an
2026-11-01
Not yet open
Anhui Medical University
Not applicable
100
Hefei
2026-11-01
Not yet open
Hansoh BioMedical R&D Company
Phase 3
460
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Shaoguan, Nanning, Harbin
2026-11-01
Not yet open
First Hospital of China Medical University
Observational
2,400
Hefei, Chongqing, Fuzhou, Zhangzhou, Lanzhou, Tianshui, Guangzhou, Shantou
2026-11-01
Not yet open
Dermavon Holdings Limited
Phase 3
174
Hefei, Beijing, Chongqing, Guangzhou, Jiangmen, Shenzhen, Nanning, Chengde
2026-11
Not yet open
Suzhou Biomissile Pharmaceuticals Co., Ltd.
Phase 1/2
90
Hefei
2026-11
Not yet open
Beijing Suncadia Pharmaceuticals Co., Ltd
Phase 1
50
Hefei
2026-11
Not yet open
Techpool Bio-Pharma Co., Ltd.
Phase 1
40
Hefei
2026-11
Not yet open
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1
40
Hefei
2026-10-30
Recruiting
Pfizer
Phase 3
432
Hefei, Beijing, Huizhou, Zhengzhou, Nanjing, Nanchang
2026-10-28
Recruiting
Beijing HuiLongGuan Hospital
Not applicable
80
Hefei
2026-10-16
Not yet open
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
198
Hefei
2026-10-15
Not yet open
Nanfang Hospital, Southern Medical University
Phase 1/2
49
Hefei, Beijing, Fuzhou, Dongguan, Guangzhou, Huizhou, Maoming, Shenzhen
2026-10-10
Recruiting
Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure
NCT07575672HFpEF - Heart Failure With Preserved Ejection Fraction, TAVI(Transcatheter Aortic Valve Implantation), Finerenone
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
2,832
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Zhengzhou
2026-10-09
Recruiting
The First Affiliated Hospital of Anhui Medical University
Phase 3
616
Hefei
2026-10-06
Not yet open
Anhui Medical University
Observational
120
Hefei
2026-10-01
Not yet open
First Affiliated Hospital of Ningbo University
Observational
100
Hefei, Zhejiang, Shanghai
2026-10-01
Not yet open
Anhui Provincial Hospital
Phase 2
35
Hefei
2026-10-01
Not yet open
Anhui Medical University
Not applicable
50
Hefei
2026-10-01
Not yet open
Anhui Medical University
Observational
100
Hefei
2026-10-01
Not yet open
Shanghai Mental Health Center
Observational
500
Chaohu, Hefei, Beijing, Fuzhou, Foshan, Shantou, Zhongshan, Harbin
2026-10-01
Not yet open
Shanghai East Hospital
Not applicable
400
Beijing, Hefei, Shanghai
2026-10-01
Not yet open
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
292
Bozhou, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2026-10
Not yet open
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
280
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan
2026-10
Recruiting
Beijing Sungen Biomedical Technology Co., Ltd
Phase 2
129
Chengdu, Guizhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing, Ningbo
2026-09-30
Not yet open
The Second Hospital of Anhui Medical University
Phase 2
36
Hefei
2026-09-30
Recruiting
A Study of ATG-201 in Adult Participants With Autoimmune Diseases
NCT07732309Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Sjogren's Disease, Autoimmune Diseases
Antengene Biologics Limited
Phase 1
149
Bengbu, Hefei, Beijing, Xiamen, Guangzhou, Luoyang, Zhengzhou, Wuhan
2026-09-26
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Not applicable
300
Beijing, Changsha, Chengdu, Guangzhou, Hefei, Jiaxing, Jining, Kunming
2026-09-26
Recruiting
Waterstone Pharmaceutical (Wuhan) Co., LTD.
Phase 3
300
Anqing, Hefei, Wuhu, Xuancheng, Beijing, Xiamen, Lanzhou, Guangzhou
2026-09-25
Recruiting
Pfizer
Phase 3
300
Hefei, Beijing, Chongqing, Huizhou, Hengshui, Shijiazhuang, Harbin, Luoyang
2026-09-24
Not yet open
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
92
Hefei
2026-09-22
Not yet open
Renal Oxygenation-Guided AKI Reduction Trial
NCT07816640Acute Kidney Injury, Hepatectomy
Chinese PLA General Hospital
Not applicable
1,200
Hefei, Beijing, Chongqing, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2026-09-20
Not yet open
Treatment Strategy for Patients With RA-ILD
NCT07643038Rheumatoid Arthritis Associated Interstitial Lung Disease
Chinese SLE Treatment And Research Group
Phase 4
204
Luoyang, Beijing, Changchun, Chongqing, Dalian, Handan, Hangzhou, Hefei
2026-09-20
Recruiting
Antengene Biologics Limited
Phase 3
380
Bengbu, Fuyang, Hefei, Beijing, Chongqi, Fuzhou, Lanzhou, Wuwei
2026-09-17
Recruiting
Anhui Provincial Hospital
Phase 2
60
Hefei
2026-09-16
Not yet open
InventisBio Co., Ltd
Phase 1
60
Hefei
2026-09-16
Recruiting
The First in Human Study of QLS2319 in Healthy Subjects and Cancer Cachexia
NCT07735104Cancer Cachexia, Cancer Cachexia Syndrome
Qilu Pharmaceutical Co., Ltd.
Phase 1/2
88
Hefei, Guangzhou
2026-09-16
Active, closed
The Second Hospital of Anhui Medical University
Not applicable
90
Hefei
2026-09-15
Not yet open
The First Affiliated Hospital of Anhui Medical University
Observational
3,000
Hefei
2026-09-11
Recruiting
InSilico Medicine Hong Kong Limited
Phase 3
320
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Nanning, Haikou, Shijiazhuang
2026-09-09
Not yet open
Helixon Biotechnology (Suzhou) Co., Ltd
Phase 1
32
Hefei
2026-09-09
Recruiting
Jiangsu Jingze Biopharmaceutical Co., Ltd.
Phase 2
48
Hefei, Beijing, Lanzhou, Shenzhen, Nanning, Shijiazhuang, Wuhan, Changchun
2026-09-08
Not yet open
Shuangyue Liu
Not applicable
30
Hefei, Beijing, Nanjing, Xuzhou, Dalian, Shanghai, Xi’an, Chengdu
2026-09-07
Recruiting
AstraZeneca
Not applicable
540
Chengdu, Chifeng, Dongyang, Hefei, Hengyang, Heze, Jiaxing, Langfang
2026-09-05
Active, closed
A Pharmacokinetic Study of HDM1005 Injection at Different Injection Sites
NCT07828197Overweight and/or Obesity, Healthy Participants
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
135
Hefei
2026-09-03
Recruiting
Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis
NCT07796516Difficult-to-treat Rheumatoid Arthritis, Rheumatoid Arthritis
Peking University People's Hospital
Phase 2
420
Hefei, Beijing, Chongqing, Quanzhou, Guangzhou, Jiangmen, Shenzhen, Nanning
2026-09-01
Recruiting
Transcranial Random Noise (tRNS) for BPSD in Alzheimer's Disease: A Double-blind Randomized Controlled Trial
NCT07827196Transcranial Random Noise Stimulation (tRNS), Electroencephalography, Alzheimer Disease, BPSD (Behavioral and Psychological Symptoms of Dementia)
Anhui Medical University
Not applicable
40
Hefei
2026-09-01
Recruiting
Glycoprotein IIb/IIIa PET/CT in Various GPIIb/IIIa-Related Disease
NCT07813559Thrombi, Thrombus, Brain, Thrombus
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2026-09-01
Recruiting
Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
NCT07718126Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis, Living Liver Donors
West China Hospital
Phase 4
60
Hefei, Beijing, Chongqing, Chengdu
2026-09-01
Not yet open
Effects of a Large Language Model-Driven Chatbot on Reproductive Concerns After Cancer
NCT07741266Chatbot, Large Language Model, Adolescent and Young Adult Cancer Survivors, Reproductive Health
The Hong Kong Polytechnic University
Not applicable
60
Hefei
2026-09-01
Not yet open
Shandong Suncadia Medicine Co., Ltd.
Phase 1
78
Hefei
2026-09
Not yet open
Anhui Provincial Hospital
Observational
580
Hefei
2026-09
Not yet open
Zhongshan Sansure Hygene Biomedicine Co., Ltd.
Phase 3
240
Hefei, Beijing, Xiamen, Guangzhou, Tangshan, Wuhan, Changsha, Nanjing
2026-09
Not yet open
Anhui Medical University
Not applicable
70
Hefei
2026-08-27
Recruiting
Eli Lilly and Company
Phase 3
2,001
Chengdu, Hefei, Jinan, Luoyang Shi, Nanjing, Ningbo, Qinhuangdao Shi, Tianjin
2026-08-26
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1
145
Hefei, Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Shanghai
2026-08-25
Recruiting
Ocumension Therapeutics (Suzhou) Co., Ltd
Phase 3
842
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou
2026-08-25
Recruiting
Novartis Pharmaceuticals
Phase 2
344
Hefei, Taiyuan, Beijing
2026-08-24
Recruiting
AstraZeneca
Phase 3
351
Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Hefei, Huangshi
2026-08-21
Recruiting
Tasly Pharmaceutical Group Co., Ltd
Phase 3
636
Bozhou, Hefei, Suzhou, Beijing, Fuzhou, Lanzhou, Qingyang, Dongguan
2026-08-21
Not yet open
China National Center for Cardiovascular Diseases
Observational
640
Hefei, Beijing, Shenzhen
2026-08-17
Recruiting
SMP-656 for HER2-Positive Advanced Breast Cancer
NCT07726342HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
Chengdu SciMount Pharmatech Co., Ltd.
Phase 2
60
Hefei, Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Nanjing
2026-08-10
Not yet open
Effectiveness of an AI-Enabled Mobile Intervention on Lifestyle Behaviors and Maternal-Infant Health
NCT07582068Mobile Health Apps, Lifestyle Intervention, Prevention, Multi-component Based Behavioral Intervention
Fangbiao Tao
Not applicable
400
Hefei
2026-08-10
Recruiting
InventisBio Co., Ltd
Phase 1
40
Hefei
2026-08-08
Recruiting
Shuanghu Yuan
Not applicable
84
Hefei, Nanjing
2026-08-05
Not yet open
The First Affiliated Hospital of Anhui Medical University
Phase 1
10
Hefei
2026-08-03
Not yet open
Vigonvita Life Sciences
Phase 1
16
Hefei
2026-08-01
Recruiting
Endovascular Therapy for Acute Basilar Artery Occlusion With Large Ischemic Core
NCT07672795Acute Ischemic Stroke, Basilar Artery Occlusion, Large Ischemic Core
The First Affiliated Hospital of University of Science and Technology of China
Not applicable
256
Hefei
2026-08-01
Recruiting
Clinical Application of a Low-Dose CBCT AI Model
NCT07845929Cerebrovascular Diseases, Lung, Liver
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
1,380
Hefei, Wuhan, Nanjing
2026-08-01
Not yet open
Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Phase 1/2
55
Hefei, Beijing, Guangzhou, Shenzhen, Wuhan, Changsha, Nanjing, Chengdu
2026-08
Not yet open
Laekna Limited
Phase 1
150
Hefei, Beijing, Changchun, Shanghai, Hangzhou
2026-08
Recruiting
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
NCT07521007Atherosclerosis, Coronary Artery Disease
Beijing Inno Medicine Co., Ltd.
Phase 2
456
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Daqing, Harbin, Wuhan
2026-07-31
Recruiting
Boehringer Ingelheim
Phase 3
448
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Luoyang
2026-07-27
Recruiting
Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)
NCT07744698Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Anhui Provincial Cancer Hospital
Phase 4
107
Hefei
2026-07-24
Recruiting
Network-Guided Individualized TMS for BPSD in Alzheimer's Disease: A Double-blind Randomized Controlled Trial
NCT07692542Transcranial Magnetic Stimulation, Behavioral and Psychological Symptoms in Alzheimer's Disease, Individualized Navigation
Anhui Medical University
Not applicable
40
Hefei
2026-07-20
Recruiting
The First Affiliated Hospital of Anhui Medical University
Phase 4
285
Hefei, Taiyuan, Wenzhou, Chongqing
2026-07-16
Not yet open
Anhui Provincial Cancer Hospital
Phase 2
39
Hefei
2026-07-15
Not yet open
Huan Zhou
Not applicable
20
Hefei, Shanghai
2026-07-13
Not yet open
Jiangsu Carephar Pharmaceutical Co., Ltd.
Phase 2
156
Beijing, Bengbu, Changsha, Chongqing, Fujian, Guangzhou, Hefei, Huizhou
2026-07-12
Recruiting
A Study of MI078 for Postpartum Depression
NCT07721961Postpartum Depression (PPD)
Nanjing Minova Pharmaceutical Co., Ltd.
Phase 3
200
Hefei, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhaoqing, Liuzhou, Guiyang
2026-07-10
Recruiting
AstraZeneca
Phase 3
600
Changsha, Hefei, Huai'an, Langfang, Liangyugang, Luoyang, Nanjing, Nanyang
2026-07-08
Recruiting
AstraZeneca
Phase 3
1,200
Changsha, Hefei, Huai'an, Langfang, Liangyugang, Luoyang, Nanjing, Nanyang
2026-07-06
Recruiting
Hoffmann-La Roche
Phase 3
300
Zhengzhou, Xianyang, Ningbo, Beijing, Changchun, Hefei, Herbin, Huai'an
2026-07-03
Not yet open
Zishen Yutai Pill for Patients With Recurrent Implantation Failure
NCT07641088Recurrent Implantation Failure
Peking University Third Hospital
Not applicable
878
Hefei, Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Changsha, Nanjing, Xi'an
2026-07-01
Not yet open
Red Dichromatic Imaging for Improving Post-Biopsy Bronchoscopic Field Visibility
NCT07653945Bronchoscopic Biopsy, Airway Lesion, Biopsy-related Bleeding
First Affiliated Hospital of Ningbo University
Observational
206
Hefei, Zhejiang, Shanghai
2026-07-01
Not yet open
Anhui Medical University
Not applicable
75
Hefei
2026-07-01
Recruiting
Zhiquan Hu
Phase 3
170
Hefei, Fuzhou, Xiamen, Guangzhou, Shenzhen, Enshi, Huanggang, Huangshi
2026-07-01
Recruiting
Climb Bio, Inc.
Phase 1/2
30
Mianyang, Baoji, Beijing, Bengbu, Changsha, Hefei, Nanchang, Suzhou
2026-06-30
Not yet open
A Clinical Study of ZL-85FA Tablets
NCT07339748Advanced Solid Tumor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1/2
51
Hefei
2026-06-30
Not yet open
Sinovac Life Sciences Co., Ltd.
Phase 3
600
Fuyang, Hefei, Beijing, Guangzhou, Shenzhen, Liuzhou, Zunyi, Shijiazhuang
2026-06-28
Recruiting
Monoamine Oxidase B PET/CT in Various MAO-B-Related Disease
NCT07685873Parkinson Disease, Parkinson Disease Dementia, Parkinson's Disease and Parkinsonism
Tianjin Medical University
Observational
200
Hefei, Qingdao, Tianjin
2026-06-25
Recruiting
Monoamine Oxidase A PET/CT in Various MAO-A-Related Disease
NCT07685860Depression, Anxiety, Heart Injuries
Tianjin Medical University
Observational
200
Hefei, Qingdao, Tianjin
2026-06-25
Recruiting
AstraZeneca
Phase 2
84
Anyang, Beijing, Changsha, Chengdu, Chizhou, Haikou, Hefei, Hohhot
2026-06-24
Recruiting
TCRx Therapeutics Co.Ltd
Observational
200
Bengbu, Hefei
2026-06-22
Recruiting
West China Second University Hospital
Not applicable
62
Hefei, Nanning, Guiyang, Zunyi, Nanchang, Xi'an, Chengdu, Ürümqi
2026-06-19
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
51
Hefei, Fuzhou, Guangzhou, Nanning, Cangzhou, Chengde, Shijiazhuang, Xingtai
2026-06-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
310
Hefei, Beijing, Xiamen, Guangzhou, Guilin, Nanning, Shijiazhuang, Wuhan
2026-06-18
Recruiting
The United Bio-Technology (Hengqin) Co., Ltd.
Phase 1
53
Hefei
2026-06-17
Not yet open
Chinese University of Hong Kong
Phase 2
200
Hefei, Wenzhou
2026-06-15
Not yet open
CS-121 APOC3 Base Editing in Severe Hypertriglyceridemia
NCT07657780Severe Hypertriglyceridemia (sHTG)
DrugCS-121
CorrectSequence Therapeutics Co., Ltd
Early Phase 1
15
Hefei
2026-06-15
Active, closed
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
60
Tianjin, Fuyang, Fuzhou, Guangzhou, Hefei, Jinan, Kunming, Nanning
2026-06-12
Not yet open
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1
12
Hefei
2026-06-10
Recruiting
Anhui Medical University
Not applicable
88
Hefei
2026-06-03
Recruiting
Shenzhen Core Medical Technology CO.,LTD.
Not applicable
6
Hefei, Beijing
2026-06-02
Recruiting
China Metastatic Liver Cancer Clinical Registry Cohort Database
NCT07602504Liver Metastases, Metastases to Liver, Liver Cancer, Neoplasms
Anhui Provincial Hospital
Observational
2,000
Bengbu, Hefei, Qingdao
2026-06-01
Recruiting
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of HS-10506
NCT07844967Hepatic Impairment (Moderate or Mild) & Normal Hepatic Function
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
32
Hefei
2026-06-01
Recruiting
Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients
NCT07618936PD-L1 Gene Mutation, PD-L1 Gene Amplification, PD-L1-related Disease, Positron Emission Tomography
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2026-06-01
Not yet open
Anhui Provincial Cancer Hospital
Observational
150
Hefei
2026-06-01
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
260
Bengbu, Hefei, Beijing, Chongqing, Lanzhou, Guangzhou, Zhanjiang, Nanning
2026-06
Not yet open
The Second Hospital of Anhui Medical University
Not applicable
136
Hefei
2026-06
Not yet open
The Second Hospital of Anhui Medical University
Not applicable
186
Hefei
2026-06
Not yet open
Peking Union Medical College Hospital
Observational
2,000
Hefei, Beijing, Linxia, Qinzhou, Guiyang, Zunyi, Tangshan, Mudanjiang
2026-05-30
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
500
Hefei, Beijing, Fuzhou, Xiamen, Shijiazhuang, Zhengzhou, Shiyan, Wuhan
2026-05-28
Recruiting
The United Bio-Technology (Hengqin) Co., Ltd.
Phase 1
48
Hefei
2026-05-27
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals
Phase 3
460
Hefei, Guangzhou, Wuhan, Nanjing, Nantong, Nanchang, Changchun, Jinan
2026-05-27
Recruiting
AstraZeneca
Phase 4
100
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2026-05-26
Recruiting
Shanghai Henlius Biotech
Phase 1
258
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou
2026-05-25
Recruiting
BeOne Medicines
Phase 3
1,056
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shantou, Nanning
2026-05-22
Recruiting
Huahui Health
Phase 1/2
30
Bengbu, Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou
2026-05-19
Recruiting
Adaptive DBS for PD
NCT07635823Parkinson Disease(PD)
Beijing Pins Medical Co., Ltd
Not applicable
60
Hefei, Beijing, Guangzhou, Changsha, Nanjing, Jinan, Chengdu
2026-05-16
Not yet open
Foresight Therapeutics (Hefei) Co., Ltd.
Phase 1
156
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Changchun
2026-05-15
Recruiting
Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD
NCT07632677Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis, Metabolic Dysfunction-associated Fatty Liver Disease
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
10,000
Bengbu, Hefei, Wuhu, Guangzhou, Shenzhen, Nanning, Zunyi, Haikou
2026-05-15
Not yet open
Shanghai Henlius Biotech
Phase 1
24
Hefei
2026-05-14
Recruiting
Vigonvita Life Sciences
Phase 1
12
Hefei
2026-05-11
Recruiting
Ningbo Newbay Technology Development Co., Ltd
Phase 2/3
255
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Shijiazhuang
2026-05-11
Recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1
16
Hefei
2026-05-10
Recruiting
A Clinical Study of Cizutamig in Thyroid Eye Disease
NCT07597200Thyroid Eye Disease, TED
Candid Therapeutics
Phase 1
38
Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Changsha, Wuhan, Nanchang
2026-05-08
Recruiting
SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracranial Hemorrhage (SAFER-AF)
NCT07316270AF - Atrial Fibrillation, Intracranial Hemorrhage, Spontaneous
Beijing Anzhen Hospital
Not applicable
646
Hefei, Beijing, Xiamen, Harbin, Changchun, Xi'an
2026-05-06
Not yet open
Sinovac Biotech Co., Ltd
Phase 3
6,000
Hefei, Fujian, Henan, Hubei, Sichuan
2026-05
Not yet open
Kunming Pharmaceuticals, Inc.
Phase 2
100
Hefei, Beijing, Chongqing, Guangzhou, Changsha, Shenyang, Kunming, Hangzhou
2026-04-30
Recruiting
Eli Lilly and Company
Phase 3
140
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei
2026-04-30
Not yet open
Shanghai Henlius Biotech
Phase 1
24
Hefei
2026-04-30
Recruiting
TIS for NSSI in Adolescent Depression
NCT07554755Temporal Interference Stimulation, Non Suicidal Self Injury, Major Depressive Disorder
The Second Hospital of Anhui Medical University
Not applicable
60
Hefei
2026-04-30
Recruiting
Bayer
Phase 2
250
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2026-04-27
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
105
Hefei, Beijing, Chongqing, Fuzhou, Dongguan, Guangzhou, Shijiazhuang, Zhengzhou
2026-04-27
Recruiting
BioNTech SE
Phase 3
736
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Hefei, Nanchang
2026-04-22
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
752
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2026-04-15
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
800
Chizhou, Hefei, Chongqing, Zhangzhou, Lanzhou, Foshan, Shenzhen, Guiyang
2026-04-14
Active, closed
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
60
Tianjin, Fuyang, Fuzhou, Ganzhou, Guangzhou, Hefei, Huai'an, Jinan
2026-04-14
Recruiting
Vigonvita Life Sciences
Early Phase 1
24
Hefei
2026-04-13
Not yet open
Anhui Provincial Hospital
Phase 4
160
Hefei
2026-04-10
By invitation
Shanghai United Cell Biotechnology Co., Ltd
Phase 4
6,000
Hefei, Beijing, Wuhan, Nanjing, Jinan
2026-04-10
Not yet open
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
42
Hefei
2026-04-08
Recruiting
RemeGen Co., Ltd.
Phase 3
574
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Dongguan, Guangzhou
2026-04-03
Active, closed
A Study of CS060380 Tablets in Patients With MASH and Obesity
NCT07466017Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity
Cascade Pharmaceuticals, Inc
Phase 2
130
Hefei, Guangzhou, Shijiazhuang, Nanjing, Shanghai, Hangzhou, Ningbo, Wenzhou
2026-04-02
Not yet open
Simultaneous Vs Staged VPS and CP :A Multi-cnter RCT.
NCT07462676Ventriculoperitoneal Shunt (VPS), Cranioplasty
Anhui Provincial Hospital
Not applicable
300
Hefei
2026-04-01
Recruiting
UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT07530380AIHA - Warm Autoimmune Hemolytic Anemia, UCART
The Second Hospital of Anhui Medical University
Early Phase 1
15
Hefei
2026-04
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
177
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning, Guiyang
2026-03-31
Active, closed
A Phase I Study of SIM0532 in Adult Participants With Advanced Solid Tumors
NCT07749703Histologically or Cytologically Confirmed Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
346
Hefei, Shenyang, Jinan, Shanghai, Hangzhou
2026-03-31
Recruiting
The Second Hospital of Anhui Medical University
Not applicable
50
Hefei
2026-03-30
Recruiting
Fujian Medical University
Not applicable
1,312
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Dalian
2026-03-29
Recruiting
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 2/3
680
Hefei, Shanghai
2026-03-27
Recruiting
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase 3
300
Beijing, Chengdu, Guangdong, Guangzhou, Hefei, Huai'an, Kaifeng, Kunming
2026-03-27
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
60
Hefei, Beijing, Xiamen, Zhengzhou, Xuzhou, Jinan, Hangzhou
2026-03-27
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Eli Lilly and Company
Phase 2
1,431
Binzhou, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Harbin, Hefei
2026-03-26
Recruiting
Beijing Continent Pharmaceutical Co, Ltd.
Phase 2/3
298
Hefei, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou, Maoming, Shenzhen
2026-03-26
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
440
Anqing, Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou
2026-03-24
Not yet open
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Phase 2
250
Hefei, Nanning, Haikou, Jingzhou, Wuhan, Changsha, Hengyang, Nanchang
2026-03-23
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
46
Hefei
2026-03-20
Recruiting
Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07787273Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy, Camrelizumab
Hefei Cancer Hospital of the Chinese Academy of Sciences
Phase 2
84
Hefei
2026-03-20
Recruiting
Anti CD19 Gene Therapy for B-cell Lymphoma
NCT07211048B-cell Lymphoma
Anhui Provincial Hospital
Not applicable
18
Hefei
2026-03-20
Not yet open
The First Affiliated Hospital of University of Science and Technology of China
Phase 2/3
750
Hefei
2026-03-17
Recruiting
tACS for Self-Other Boundary in Schizophrenia
NCT07818668Schizophrenia / Schizoaffective Disorder
Chunyan Zhu
Not applicable
100
Hefei
2026-03-17
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Zhenjiang, Xianyang, Jinan, Beijing, Changchun, Hefei, Herbin, Huizhou
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 1/2
198
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Nanyang
2026-03-16
Recruiting
Effect of EIT-guided PEEP in ARDS Patients
NCT06990477ARDS (Acute Respiratory Distress Syndrome)
Southeast University, China
Not applicable
2,400
Hefei, Shanghai, Guangzhou, Zhengzhou, Hangzhou, Nanjing, Xuzhou, Nanchang
2026-03-13
Not yet open
The First Affiliated Hospital of Soochow University
Phase 3
204
Hefei, Luoyang, Wuhan, Changzhou, Huai'an, Jingjiang, Lianyungang, Nanjing
2026-03-10
Not yet open
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase 1
60
Hefei
2026-03-09
Recruiting
Phase II Study of RC1416 Injection in COPD
NCT07402551Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
DrugRC1416
Nanjing RegeneCore Biotech Co., Ltd.
Phase 2
180
Hefei, Suzhou, Chongqing, Xiamen, Guangzhou, Huizhou, Jiangmen, Qingyuan
2026-03-06
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Beijing, Changsha, Cheng Du Shi, Dongguan, Guangzhou, Hangzhou, Hefei, Jinhua
2026-03-05
Recruiting
ART Trial: Transcatheter J-VALVE Versus Surgery for Aortic Regurgitation Therapy
NCT07453407Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,250
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Hong Kong, Wuhan, Changsha
2026-03-05
Recruiting
West China Hospital
Observational
2,000
Hefei, Chongqing, Guangzhou, Harbin, Wuhan, Nanjing, Tianjin
2026-03-01
Not yet open
Anhui Medical University
Not applicable
60
Hefei
2026-03-01
Active, closed
Health Coaching for Self-Management in Maintenance Hemodialysis Patients
NCT07685626End-Stage Kidney Disease (ESKD), Maintenance Hemodialysis (MHD)
Anhui Medical University
Not applicable
60
Hefei
2026-03-01
Not yet open
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
142
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Meizhou
2026-03
Recruiting
Antengene Biologics Limited
Phase 1/2
132
Hefei, Beijing, Fuzhou, Xiamen, Lanzhou, Langfang, Shijiazhuang, Anyang
2026-02-27
Recruiting
AstraZeneca
Phase 3
508
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Nanchang, Nanjing
2026-02-23
Not yet open
Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)
NCT07393438Multidrug-Resistant Tuberculosis, Rifampicin-resistant Tuberculosis, MDR-TB, RR-TB
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
120
Hefei, Shanghai
2026-02-21
Recruiting
West China Second University Hospital
Not applicable
120
Chengdu, Guiyang, Hefei, Jiangxi, Kunming, Nanning, Ürümqi, Xi'an
2026-02-13
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
105
Hefei, Beijing, Fuzhou, Lanzhou, Shantou, Nanning, Guangxi, Zunyi
2026-02-12
Recruiting
Pfizer
Phase 2/3
1,156
Chizhou, Fuyang, Hefei, Beijing, Chongqing, Guangzhou, Huizhou, Xinxiang
2026-02-11
Recruiting
Eli Lilly and Company
Phase 3
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Kunming
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
900
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hefei, Huzhou
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
1,000
Beijing, Changsha, Chaohu, Chengdu, Guangzhou, Haidian District, Hefei, Huzhou
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
900
Beijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Hefei, Jinan
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
1,980
Beijing, Chengdu, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang, Nanjing
2026-02-06
Recruiting
Shanghai Henlius Biotech
Phase 2
120
Hefei, Fu'zhou, Guangzhou, Nanning, Cangzhou, Harbin, Xinxiang, Wuha
2026-02-05
Recruiting
AlphaNa Bioscience Company Limited
Early Phase 1
18
Hefei
2026-02-04
Recruiting
Eli Lilly and Company
Phase 1
68
Beijing, Changsha, Hefei, Shanghai, Wenzhou, Wuhan
2026-02-04
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
111
Harbin, Hefei, Shanghai, Xi'an, Zhengzhou
2026-02-01
Recruiting
Efficacy of Montelukast on STEMl Patients
NCT07320625Myocardial Infarction (MI)
Shanghai Zhongshan Hospital
Phase 3
512
Dalian, Shanghai, Fuzhou, Guangdong, Ha’erbin, Hefei, Hunan, Shenyang
2026-02-01
Active, closed
Shuanghu Yuan
Observational
30
Hefei
2026-02-01
Not yet open
MindRank AI Ltd
Phase 3
738
Beijing, Changchun, Changde, Changsha, Datong, Dongyang, Ganzhou, Hefei
2026-02
Active, closed
The First Affiliated Hospital of Anhui Medical University
Not applicable
90
Hefei
2026-01-31
Recruiting
Vigonvita Life Sciences
Phase 1
56
Hefei
2026-01-29
Recruiting
Study of Predicting Lymph Node Metastasis of High-risk Prostate Cancer by Artificial Intelligence Multi-omics Analysis
NCT07112599Prostate Cancer, Lymph Node Cancer Metastatic, Artificial Intelligence (AI)
Anhui Medical University
Observational
2,000
Hefei
2026-01-25
Recruiting
Sanofi
Phase 3
751
Guangzhou, Huizhou, Wuxi, Chengdu, Beijing, Hefei, Kunming, Shanghai
2026-01-16
Recruiting
Innostellar Biotherapeutics Co.,Ltd
Phase 3
388
Hefei, Beijing, Chongqing, Guangzhou, Shantou, Zhongshan, Xingtai, Harbin
2026-01-14
Recruiting
Shanghai SciBrunch Therapeutics Co., Ltd.
Phase 1/2
210
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Xuzhou, Shenyang
2026-01-08
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer
Phase 3
1,410
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Huizhou, Jiangmen, Nanning
2026-01-06
Recruiting
Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion
NCT07185022Stroke, Cerebrovascular Disorders, Brain Diseases, Nervous System Diseases
The Second Hospital of Anhui Medical University
Not applicable
282
Fuyang, Hefei, Lu'an, Liuzhou, Lishui
2026-01-06
Active, closed
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase 1
144
Hefei
2026-01-04
Recruiting
Vigonvita Life Sciences
Phase 1
58
Hefei
2026-01-04
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning
2026-01-02
Recruiting
Acepodia Biotech, Inc.
Phase 1/2
34
Beijing, Chengdu, Hangzhou, Hefei, Shanghai, Taiyuan, Wuhan
2026-01-01
Not yet open
Left Ventricular Myocardial Work for Predicting Response to CRT
NCT07319065CRT Non-Response, LBBB, HF - Heart Failure, Healthy Adult
First Hospital of China Medical University
Observational
3,240
Hefei, Wannan, Fuzhou, Guizhou, Xiamen, Lanzhou, Jiangmen, Qinhuangdao
2026-01-01
Active, closed
The Children's Hospital of Zhejiang University School of Medicine
Observational
300
Hefei, Suzhou, Kunming, Hangzhou, Wenling
2026-01-01
Not yet open
TransThera Sciences (Nanjing), Inc.
Phase 3
138
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2026-01
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Hefei, Chongqing, Fuzhou, Fuzhou Fujian, Guangzhou, Shenzhen, Nanning, Tianjin
2025-12-31
Recruiting
DSciLab Co., Ltd.
Early Phase 1
18
Hefei
2025-12-31
Recruiting
Xian-Janssen Pharmaceutical Ltd.
Phase 4
78
Guangzhou, Hangzhou, Hefei, Shanghai
2025-12-30
Recruiting
Alpha Biopharma (Jiangsu) Co., Ltd.
Observational
800
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Meizhou
2025-12-29
Recruiting
Celest Therapeutics (Shanghai) Co., Ltd.
Early Phase 1
18
Hefei
2025-12-27
Recruiting
Noninvasive Real-Time Arterial Waveform Monitoring for Cardiovascular Disease Assessment
NCT07350629Aortic Regurgitation Disease, Aortic Stenosis Disease, Healthy Subjects
Anhui Provincial Cancer Hospital
Observational
15
Hefei
2025-12-26
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
560
Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Guangzhou, Meizhou, Shantou
2025-12-24
Recruiting
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase 1
40
Hefei
2025-12-23
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Shantou
2025-12-17
Recruiting
Hutchmed
Phase 1/2
147
Beijing, Changsha, Guangzhou, Hefei, Shanghai, Shenyang, Zhengzhou
2025-12-16
Recruiting
Eli Lilly and Company
Phase 3
1,035
Beijing, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang
2025-12-15
Recruiting
Hangzhou Qihan Biotech Co., Ltd.
Phase 1
18
Hefei, Wuhan, Beijing
2025-12-15
Recruiting
Shanghai Zhongshan Hospital
Phase 4
1,316
Hefei, Huizhou, Shenzhen, Harbin, Xinxiang, Wuhan, Changsha, Hengyang
2025-12-13
Recruiting
Pfizer
Phase 3
800
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou, Nanning
2025-12-11
Recruiting
JHM BioPharma (Tonghua) Co. , Ltd.
Phase 3
207
Bengbu, Hefei, Beijing, Chongqing, Guangzhou, Nanning, Cangzhou, Shijiazhuang
2025-12-11
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
566
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-12-02
Recruiting
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2
60
Hefei
2025-12-02
Recruiting
Sunshine Lake Pharma Co., Ltd.
Phase 1
78
Hefei
2025-12-02
Not yet open
The First Affiliated Hospital of Anhui Medical University
Phase 4
1,036
Hefei
2025-12-01
Recruiting
The First Affiliated Hospital of Anhui Medical University
Not applicable
40
Hefei
2025-12-01
Recruiting
Cascade Pharmaceuticals, Inc
Phase 3
135
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhanjiang, Nanning
2025-12-01
Not yet open
Akeso
Phase 1
108
Hefei
2025-12
Not yet open
A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
NCT07239986Hepatocellular Carcinoma (HCC)
DrugBB102
Broadenbio Ltd., Co.
Phase 2
60
Hefei, Shanghai
2025-12
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Hefei, Fuzhou, Xiamen, Guangzhou, Naning, Heilongjiang, Shijiazhuang, Zhengzhou
2025-11-30
Recruiting
Vigonvita Life Sciences
Phase 1
16
Hefei
2025-11-28
Recruiting
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2
150
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Nanning, Shijiazhuang
2025-11-27
Recruiting
Shanghai RAAS Blood Products Co., Ltd.
Phase 2
24
Changsha, Hefei, Jinan, Nanning, Suzhou, Taiyuan, Tangshan, Tianjin
2025-11-26
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301IO Resistant Squamous and Nonsquamous NSCLC
Takeda
Phase 3
1,200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Xinxiang
2025-11-26
Recruiting
Ming-Yuan Chen
Phase 3
346
Hefei, Fuzhou, Guangzhou, Shantou, Zhongshan, Zhuhai, Nanning, Wuzhou
2025-11-20
Recruiting
The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
NCT07150624Hepatocellular Carcinoma (HCC), Liver Diseases
Anhui Provincial Hospital
Phase 4
96
Hefei
2025-11-10
Recruiting
Zhimin Zhai
Phase 1/2
24
Hefei
2025-11-10
Recruiting
The First Affiliated Hospital of University of Science and Technology of China
Not applicable
406
Hefei
2025-11-05
Not yet open
Tenecteplase vs Medical Management in 4.5-24h LVO no Access to EVT
NCT07168278Acute Ischemic Stroke, Large Vessel Occlusion, Tenecteplase, Thrombolysis
The First Affiliated Hospital of University of Science and Technology of China
Phase 3
794
Hefei
2025-11-01
Recruiting
Takeda
Observational
200
Hefei, Beijing, Fuzhou, Hangzhou, Shantou, Shenzhen, Shijiazhuang, Harbin
2025-11-01
Recruiting
[18F]NIDF PET Imaging in Tau-related Diseases
NCT07306598Neurodegenerative Disease, Alzheimer s Disease, Tauopathies
Tianjin Medical University
Observational
20
Hefei, Qingdao, Tianjin
2025-11-01
Recruiting
Evaluation of the Safety and Effectiveness of CHORDS® Cerebral Protection System During TAVR: DUET Trial
NCT07648693Transcatheter Aortic Valve Replacement (TAVR), Cerebral Vascular Accident (CVA)/Stroke
Resonova (Shanghai) Medtech Limited
Not applicable
240
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanchang, Qingdao
2025-10-31
Recruiting
QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
NCT07330596NSCLC (Advanced Non-small Cell Lung Cancer)
Anhui Provincial Cancer Hospital
Phase 2
96
Hefei
2025-10-30
Recruiting
BioNTech SE
Phase 3
558
Changde, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanchang, Nanjing
2025-10-30
Recruiting
Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage
NCT07208097Intracerebral Haemorrhage, Minimally Invasive Treatment
Tongji Hospital
Not applicable
768
Anqing, Hefei, Suzhou, Guangzhou, Nanning, Bijie, Guiyang, Kaili
2025-10-25
Recruiting
KD Treatment for Super-refractory Status Epilepticus
NCT07496749Super-refractory Status Epilepticus
Xuanwu Hospital, Beijing
Not applicable
84
Hefei, Beijing, Fuzhou, Nanning, Guiyang, Haikou, Shijiazhuang, Harbin
2025-10-20
Recruiting
Personalized iTBS in Real-World Clinical Settings for Schizophrenia
NCT07176468Schizophrenia, Transcranial Magnetic Stimulation
Anhui Medical University
Not applicable
40
Hefei
2025-10-20
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 2
140
Hefei, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Xiangyang, Changsha
2025-10-20
By invitation
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase 1
118
Hefei
2025-10-19
By invitation
Celregen Therapeutics
Early Phase 1
10
Hefei
2025-10-17
Recruiting
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei
2025-10-16
Recruiting
Anhui Medical University
Not applicable
90
Hefei
2025-10-16
Recruiting
CS-121 APOC3 Base Editing in FCS
NCT07176923Familial Chylomicronemia Syndrome (FCS)
DrugCS-121
CorrectSequence Therapeutics Co., Ltd
Early Phase 1
15
Hefei
2025-10-15
Recruiting
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 1
168
Hefei
2025-10-15
Recruiting
A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
NCT07095075Relapsed/Refractory Autoimmune Diseases
Nanjing Legend Biotech Co.
Early Phase 1
36
Bengbu, Hefei, Nanjing, Suzhou, Wenzhou
2025-10-14
Recruiting
Anhui Medical University
Phase 2
216
Hefei
2025-10-10
Recruiting
Anhui Provincial Hospital
Observational
100
Hefei
2025-10-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Hefei, Beijing, Fujian, Fuzhou, Guangzhou, Nanning, Jiamusi, Zhengzhou
2025-10-08
Recruiting
Pfizer
Phase 2/3
982
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Baoding, Langfang
2025-10-03
Recruiting
Novo Nordisk A/S
Phase 3
1,280
Hefei, Beijing, Changchun, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Harbin
2025-10-02
Recruiting
TCRx Therapeutics Co.Ltd
Phase 1
30
Hefei
2025-10-01
Active, closed
Longbio Pharma
Phase 1/2
6
Hefei
2025-10-01
Active, closed
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 1
30
Hefei
2025-09-30
Recruiting
Eli Lilly and Company
Phase 3
1,000
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Lanzhou, Nanjing
2025-09-30
Recruiting
Pfizer
Phase 3
680
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Wuhan
2025-09-29
Active, closed
Shanghai Henlius Biotech
Phase 1
174
Hefei, Wuhu, Beijing, Hunan, Fuzhou, Xiamen, Lanzhou, Cangzhou
2025-09-26
Active, closed
Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
NCT07107256Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
246
Fuyang, Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-09-25
Recruiting
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
NCT07188610CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 2
100
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou
2025-09-25
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
37
Hefei, Shanghai
2025-09-25
Active, closed
Innovent Biologics Technology Limited (Shanghai R&D Center)
Phase 1
79
Hefei
2025-09-25
Recruiting
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Early Phase 1
19
Hefei
2025-09-25
Recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
111
Hefei
2025-09-24
Recruiting
Shanghai Chest Hospital
Phase 2
96
Hefei, Beijing, Zhengzhou, Shanghai
2025-09-22
Recruiting
Abbisko Therapeutics Co, Ltd
Phase 2
86
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2025-09-22
Recruiting
BioNTech SE
Phase 1/2
880
Baoding, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei
2025-09-22
Recruiting
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
NCT07154264Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal Pharmaceuticals
Phase 2
66
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Yichang, Changsha, Changzhou
2025-09-22
Recruiting
Sunshine Lake Pharma Co., Ltd.
Phase 1
126
Hefei
2025-09-21
Recruiting
Anhui Provincial Cancer Hospital
Not applicable
12
Hefei
2025-09-20
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
80
Hefei, Beijing, Guangzhou, Baoding, Harbin, Zhangzhou, Wuhan, Nanjing
2025-09-17
Active, closed
Eli Lilly and Company
Phase 3
800
Baotou, Beijing, Chongqing, Harbin, Hefei, Jinan, Luoyang, Nanjing
2025-09-15
Not yet open
Multicenter Validation Study on Autism Screening Using a Machine-assisted System
NCT07006948Autism Spectrum Disorder, Early Developmental Impairment, Language Development Disorders
Children's Hospital of Fudan University
Observational
1,000
Hefei, Xiamen, Liuzhou, Harbin, Kunshan, Xi'an, Shanghai, Chengdu
2025-09-15
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
544
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Quanzhou, Xiamen, Zhangzhou
2025-09-15
Recruiting
CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
NCT07179692Lung Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer
Chongqing Precision Biotech Co., Ltd
Phase 1
108
Hefei
2025-09-12
Recruiting
Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
NCT06824103Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease
Novartis Pharmaceuticals
Phase 4
50
Hefei, Guangzhou, Nanning, Guiyang, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2025-09-09
Recruiting
WANG KAI
Not applicable
40
Hefei
2025-09-09
Recruiting
TCM as an Adjuvant Treatment in Mycobacterium Abscessus Pulmonary Disease
NCT07295938Mycobacterium Abscessus Pulmonary Disease
Shanghai University of Traditional Chinese Medicine
Phase 2
352
Beijing, Guangdong, Hefei, Nanchang, Shanghai
2025-09-08
Recruiting
Bambusa Therapeutics
Phase 1
68
Hefei, Guangzhou, Jiangmen, Qingyuan, Xinxiang, Yichang, Xuzhou, Nanchang
2025-09-05
Active, closed
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
209
Hefei, Beijing, Sichuan, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zunyi
2025-09-02
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
414
Hefei, Fuzhou, Guangzhou, Meizhou, Nanning, Baoding, Harbin, Anyang
2025-09-02
Recruiting
Guangzhou Virotech Pharmaceutical Co., Ltd.
Phase 1/2
42
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhuhai, Nanning, Jinan
2025-09-02
Recruiting
Anhui Provincial Hospital
Phase 1
20
Hefei
2025-09-01
Not yet open
Anhui Provincial Hospital
Observational
50
Hefei
2025-09-01
Not yet open
Sivelestat Treatment for Postoperative Organ Protection in Type A Aortic Dissection
NCT07156656Type A Aortic Dissection, Organ Failure, Multiple
Shanghai Zhongshan Hospital
Phase 4
236
Hefei, Fuzhou, Guangzhou, Shenzhen, Xi'an, Shanghai
2025-09-01
Not yet open
Tasly Pharmaceutical Group Co., Ltd
Phase 3
360
Hefei, Chongqing, Guangzhou, Zunyi, Xingtai, Kaifeng, Nanyang, Sanmenxia
2025-09-01
Recruiting
Intervention Effect of Temporal Interference Stimulation (TIS) on Depressive Disorder
NCT07191392Depressive Disorder, Temporal Interference Stimulation
The Second Hospital of Anhui Medical University
Not applicable
60
Hefei
2025-09-01
Recruiting
Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease
NCT07068438Chronic Bronchitis, COPD (Chronic Obstructive Pulmonary Disease)
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
210
Hefei, Beijing, Changzhou, Suzhou, Wuxi, Xuzhou, Nanchang, Hangzhou
2025-09-01
Recruiting
Multimodal Clinical Study of Electroconvulsive Therapy and Magnetic Seizure Therapy
NCT07473648Electroconvulsive Therapy, Major Depressive Disorder, Magnetic Seizure Therapy
The Second Hospital of Anhui Medical University
Not applicable
200
Hefei
2025-09-01
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
666
Bozhou, Chizhou, Hefei, Chongqing, Fuzhou, Zhangzhou, Lanzhou, Foshan
2025-09
Recruiting
Beijing HuiLongGuan Hospital
Not applicable
60
Hefei
2025-08-30
Recruiting
Anhui Provincial Hospital
Early Phase 1
36
Hefei
2025-08-29
Recruiting
Ausper Biopharma Co., Ltd.
Observational
200
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou
2025-08-28
Recruiting
BeOne Medicines
Phase 3
351
Hefei, Beijing, Xiamen, Anyang, Zhengzhou, Nanjing, Ganzhou, Shenyang
2025-08-27
Recruiting
BioNTech SE
Phase 1/2
375
Beijing, Hefei, Henan, Hunan, Shandong, Shanghai, Sichuan, Zhejiang
2025-08-27
Recruiting
Anhui Provincial Hospital
Not applicable
18
Hefei
2025-08-25
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
75
Hefei, Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Zhengzhou
2025-08-21
Recruiting
Dizal Pharmaceuticals
Phase 1/2
150
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan
2025-08-19
Active, closed
Ausper Biopharma Co., Ltd.
Phase 3
577
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou
2025-08-12
Recruiting
Bambusa Therapeutics
Phase 1
99
Hefei, Wuhu, Beijing, Guangzhou, Changsha, Wuxi, Zhenjiang, Nanchang
2025-08-09
Recruiting
China National Center for Cardiovascular Diseases
Not applicable
4,900
Hefei, Beijing, Shenzhen, Shijiazhuang, Luoyang, Zhengzhou, Nanjing, Yangzhou
2025-08-08
Recruiting
AstraZeneca
Phase 2
278
Changsha, Chengdu, Deyang, Dongguan, Fuzhou, Guangzhou, Hangzhou, Hefei
2025-08-07
Recruiting
Beijing Anzhen Hospital
Not applicable
4,100
Hefei, Beijing, Guangzhou, Shijiazhuang, Harbin, Luohe, Zhengzhou, Wuhan
2025-08-05
Active, closed
Ferring Pharmaceuticals
Observational
2,549
Hefei, Ma’anshan, Beijing, Chaoyang, Xicheng, Guangzhou, Shantou, Nanning
2025-08-05
Active, closed
AstraZeneca
Phase 2
114
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing
2025-08-05
Recruiting
Shanghai Henlius Biotech
Phase 2
24
Beijing, Changsha, Guangzhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing
2025-08-05
Recruiting
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07093411B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory
Beijing GoBroad Hospital
Early Phase 1
48
Hefei, Xi'an, Xuzhou
2025-08-05
Recruiting
MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
NCT07391839Hepatoma, Unresectable Hepatocellular Carcinoma (HCC)
Suzhou Mednovo Yi Medical Technology Co., Ltd.
Phase 1
40
Hefei, Fuzhou, Guangzhou, Nanjing, Jinan, Hangzhou, Henan, Shanghai
2025-08-04
Recruiting
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
NCT07104721Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Systemic Sclerosis (SSc), Inflammatory Myopathy
China Immunotech (Beijing) Biotechnology Co., Ltd.
Phase 1
18
Hefei
2025-08-04
Recruiting
EVT in Acute Basilar Artery Occlusion With Large Infarction Core
NCT07090941Basilar Artery Occlusion, Large Ischemic Core, Large Core Infarct, Endovascular Treatments
The First Affiliated Hospital of Hainan Medical University
Not applicable
372
Hefei, Haikou
2025-08-01
Not yet open
Anhui Provincial Cancer Hospital
Phase 2
18
Hefei
2025-08-01
Not yet open
29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
NCT07100236Primary Hepatocellular Carcinoma
Junjie Xu
Observational
350
Hefei, Chaoyang, Fuzhou, Guangzhou, Zhengzhou, Shanghai, Hangzhou, Wenzhou
2025-08-01
Not yet open
The First Affiliated Hospital of Anhui Medical University
Not applicable
120
Hefei
2025-08-01
By invitation
The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Early Phase 1
60
Hefei
2025-08-01
Recruiting
Rescue Endovascular Treatment After Neurological Deterioration in Initially Mild Basilar Artery Occlusion in an Extended Time Window
NCT06843356Acute Mild Ischemic Stroke, Basilar Artery Occlusion, Rescue Endovascular Treatment, Extended Time Window
First Affiliated Hospital of Wannan Medical College
Not applicable
159
Hefei, Wuhu
2025-08-01
Not yet open
A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia
NCT07146386Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 3
728
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Zhangzhou, Dongguan, Shantou
2025-08
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
320
Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Zhanjiang
2025-08
Recruiting
Anhui Provincial Hospital
Early Phase 1
30
Hefei
2025-07-31
Recruiting
GeneSail Biotech (Shanghai) Co., Ltd.
Phase 1
32
Hefei, Fuzhou, Shenzhen, Zhengzhou, Changsha, Shanghai
2025-07-31
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
298
Hefei, Beijing, Xiamen, Zhengzhou, Xuzhou, Nanchang
2025-07-30
Recruiting
The First Affiliated Hospital of Anhui Medical University
Not applicable
40
Hefei
2025-07-30
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
72
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Meizhou, Shantou, Nanning
2025-07-30
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
416
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen
2025-07-25
Recruiting
Bin Cao
Phase 4
188
Hefei, Beijing, Guangzhou, Nanchang, Shanghai
2025-07-24
Recruiting
Bin Cao
Phase 4
300
Hefei, Beijing, Guangzhou, Nanchang, Shanghai
2025-07-24
Recruiting
Pfizer
Phase 3
714
Hefei, Beijing, Fuzhou, Guangzhou, Huizhou, Nanning, Harbin, Luoyang
2025-07-23
Recruiting
[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis
NCT07232459Amyloid, Cardiac Amyloidosis, Amyloidosis, Healthy Subjects
Tianjin Medical University
Observational
25
Hefei, Qingdao, Tianjin
2025-07-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Hefei, Beijing, Chongqing, Wanzhou, Fujian, Guangzhou, Jiangmen, Nanning
2025-07-21
Recruiting
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 1
48
Hefei
2025-07-20
Recruiting
Anhui Provincial Hospital
Not applicable
18
Hefei
2025-07-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Xiamen, Guangzhou, Shenzhen
2025-07-16
Recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 2
360
Chizhou, Hefei, Lanzhou, Huizhou, Jiangmen, Qingyuan, Zunyi, Langfang
2025-07-15
Recruiting
Anhui Provincial Hospital
Phase 2
97
Hefei
2025-07-14
Recruiting
Anhui Provincial Hospital
Phase 3
134
Hefei
2025-07-11
Active, closed
Anhui Provincial Cancer Hospital
Phase 1/2
20
Hefei
2025-07-07
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
246
Bengbu, Hefei, Beijing, Fuzhou, Lanzhou, Jiangmen, Nanning, Guiyang
2025-07-07
Recruiting
Hoffmann-La Roche
Phase 3
80,000
Beijing, Xuzhou, Changchun, Chengdu, Chongqing, Guangzhou, Hefei, Nanjing
2025-07-02
Recruiting
Anhui Provincial Hospital
Phase 2
37
Hefei
2025-07-01
Not yet open
Patient Journey in Advanced Gynecologic Cancers
NCT07015593Genital Neoplasms, Female, Uterine Cervical Neoplasms, Endometrial Carcinoma
Tongji Hospital
Observational
780
Hefei, Guangzhou, Wuhan, Chongqing
2025-07-01
By invitation
Junbo Ge
Not applicable
40
Hefei, Suzhou, Shanghai
2025-07-01
Active, closed
Anhui Medical University
Not applicable
28
Hefei
2025-07-01
Recruiting
Safety and Efficacy of Ventricular Irrigation for Ventriculitis
NCT06358209Central Nervous System Infections
RenJi Hospital
Not applicable
310
Hefei, Wuhu, Beijing, Fuzhou, Guangzhou, Shenzhen, Zhongshan, Harbin
2025-07-01
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
2,400
Hefei, Beijing, Xiamen, Guangzhou, Jiangmen, Liuzhou, Nanning, Xingtai
2025-06-30
Recruiting
ScinnoHub Pharmaceutical Co., Ltd.
Phase 1
96
Hefei
2025-06-27
Recruiting
Evidence-based Practice in the Management of Gastric Tube Placement in Children
NCT07038538Hospitalized Children, Nursing, Enteral Nutrition Therapy
Children's Hospital of Fudan University
Not applicable
2,750
Shanghai, Beijing, Chongqing, Gansu, Guangdong, Hefei, Henan, Hunan
2025-06-26
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
Amgen
Phase 3
5,056
Hefei, Beijing, Guangzhou, Haikou, Qinhuangdao, Shijiazhuang, Daqing, Harbin
2025-06-25
Recruiting
Stellate Ganglion Morphine Infiltration on Myocardial I/R Injury
NCT07023679Acute Myocardial Infarction (AMI)
The Second Hospital of Anhui Medical University
Not applicable
2,588
Hefei
2025-06-24
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
642
Hefei, Beijing, Lanzhou, Shantou, Harbin, Kaifeng, Puyang, Zhengzhou
2025-06-23
Recruiting
Anhui Provincial Hospital
Early Phase 1
36
Hefei
2025-06-23
Recruiting
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Not applicable
240
Hefei, Beijing, Changsha
2025-06-21
Recruiting
First Affiliated Hospital of Ningbo University
Not applicable
380
Hefei, Harbin, Ningbo, Ninghai, Taizhou
2025-06-17
Active, closed
AbbVie
Phase 3
573
Hefei, Beijing, Chongqing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2025-06-17
Recruiting
Nanfang Hospital, Southern Medical University
Phase 4
340
Hefei, Chongqing, Guangzhou, Hohhot, Ganzhou
2025-06-14
Recruiting
Abbisko Therapeutics Co, Ltd
Phase 2
141
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guilin, Liuzhou, Nanning
2025-06-13
Recruiting
Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE
NCT06892145Systemic Lupus Erythematosus (SLE), Refractory
Chongqing Precision Biotech Co., Ltd
Phase 1
12
Hefei, Hangzhou
2025-06-12
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 2
250
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Guilin, Nanning, Harbin
2025-06-11
Recruiting
BioNTech SE
Phase 3
480
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shantou
2025-06-10
Recruiting
Novartis Pharmaceuticals
Observational
80
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nantong, Nanchang, Changchun
2025-06-10
Recruiting
Boehringer Ingelheim
Phase 3
1,755
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2025-06-09
Recruiting
Celgene
Phase 2
120
Hefei, Beijing, Wuhan, Nanjing, Shanghai Shi, Hangzhou
2025-06-09
Recruiting
Nuwacell Biotechnologies Co., Ltd.
Phase 1
48
Hefei
2025-06-06
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
985
Bengbu, Hefei, Chongqing, Fuzhou, Guangzhou, Shenzhen, Liuzhou, Nanning
2025-06-05
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan
2025-06-04
Recruiting
The Effects of Daytime, Nighttime, and Combined Heat Exposure on Human Health
NCT07501923Metabolism Changes, Psychology Functional Behavior, Cardiovascular System, Respiratory System
Jian Cheng
Not applicable
35
Hefei
2025-06-01
Recruiting
Anhui Provincial Hospital
Observational
600
Hefei, Suzhou, Ningbo
2025-06-01
Recruiting
Standardized Implementation and Quality Assessment System for Confocal Enteroscopy
NCT07363291Confocal Enteroscopy, Quality Assessment System, Standardized Implementation
Shanghai Jiao Tong University School of Medicine
Observational
600
Hefei, Ningbo, Kashgar, Shanghai
2025-06-01
Active, closed
BeOne Medicines
Phase 3
153
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shenzhen, Nanning
2025-05-29
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
72
Hefei, Beijing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-05-29
Active, closed
Transcranial Direct Current Stimulation for Cancer-related Cognitive Impairment in Breast Cancer Survivors
NCT07083518Transcranial Direct Current Stimulation (tDCS), Breast Cancer Survivor, Cognitive Impairment
Anhui Medical University
Not applicable
60
Hefei
2025-05-29
Recruiting
The Second Hospital of Anhui Medical University
Not applicable
166
Hefei, Changsha
2025-05-29
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 1
30
Hefei, Beijing, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2025-05-23
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 3
500
Hefei, Fuzhou, Guangzhou, Harbin, Zhenngzhou, Wuhan, Xining, Shanghai
2025-05-22
Active, closed
Eli Lilly and Company
Phase 3
600
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-19
Active, closed
Eli Lilly and Company
Phase 3
800
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-15
Active, closed
Eli Lilly and Company
Phase 3
1,400
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-15
Recruiting
Biogen
Phase 3
454
Fuyang, Hefei, Beijing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-05-08
Recruiting
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 1
92
Hefei
2025-05-08
Recruiting
BioNTech SE
Phase 1/2
594
Hefei, Beijing, Fuzhou, Nanning, Weihui, Zhengzhou, Jingzhou, Xiangyang
2025-05-02
Recruiting
Respiratory-gated Transcutaneous Auricular Vagus Nerve Stimulation for Improving Apathy in Parkinson's Disease
NCT07118956Parkinson Disease, Apathy, Non-motor Symptoms, Vagus Nerve Stimulation
Anhui Medical University
Not applicable
60
Hefei
2025-05-01
Recruiting
CHina Adrenal Venous saMPling InvestigatiON
NCT07252284Hyperaldosteronism, Adrenal Venous Sampling, Adrenalectomy
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
5,000
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou
2025-05-01
Not yet open
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 2
180
Fuyang, Hefei, Fuzhou, Guangzhou, Shenzhen, Baise City, Shijiazhuang, Nanyang
2025-05
Not yet open
Anhui Provincial Cancer Hospital
Phase 2
20
Hefei
2025-05
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
199
Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Zhanjiang
2025-04-30
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
300
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Wuhan
2025-04-28
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
Bengbu, Hefei, Beijing, Chongqing, Fuzhou Fujian, Xiamen, Guangzhou, Shantou
2025-04-24
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
144
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Gui'lin, Liuzhou
2025-04-18
Recruiting
Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
NCT06961669Lymphoblastic Leukemia, Relapsed or Refractory Multiple Myeloma (RRMM)
Anhui Provincial Hospital
Not applicable
18
Hefei
2025-04-16
Recruiting
Beijing Anzhen Hospital
Not applicable
146
Hefei, Beijing, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2025-04-08
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
194
Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Shenzhen, Nanning, Tangshan
2025-04-08
Recruiting
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
NCT06346600Neovascular (Wet) Age-related Macular Degeneration
Skyline Therapeutics
Observational
83
Hefei, Hangzhou, Wenzhou, Beijing, Shanghai
2025-04-02
Recruiting
Child-Parent Familial Hypercholesterolemia Screening
NCT04529967Familial Hypercholesterolemia
Children's Hospital of Fudan University
Observational
15,000
Hefei, Qidong, Shanghai, Taiyuan, Chongqing, Ürümqi
2025-04-01
Recruiting
Alpha-Synuclein PET/CT in Various α-Syn-Related Disease
NCT06949670Alpha Synuclein Pathology, Alpha-Synuclein, Parkinson Disease
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2025-04-01
Not yet open
Betta Pharmaceuticals Co., Ltd.
Phase 2
100
Hefei, Lanzhou, Dongguan, Foshan, Guangzhou, Baoding, Harbin, Zhengzhou
2025-03-31
Recruiting
Gritgen Therapeutics Co., Ltd.
Phase 3
50
Hefei, Beijing, Lanzhou, Guangzhou, Tangshan, Zhengzhou, Wuhan, Changsha
2025-03-31
Recruiting
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
NCT07152041Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
150
Hefei, Chongqing, Fuzhou, Guangzhou, Guiyang, Wuhan, Changsha, Nanjin
2025-03-28
Recruiting
AstraZeneca
Phase 2
540
Baotou, Changchun, Chengdu, Chongqing, Guangzhou, Haikou, Hefei, Hohhot
2025-03-26
Active, closed
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 3
40
Hefei, Lanzhou, Guangzhou, Shenzhen, Nanning, Tangshan, Harbin, Zhengzhou
2025-03-26
Recruiting
Nanjing RegeneCore Biotech Co., Ltd.
Phase 1
71
Hefei, Guangzhou, Shenzhen, Guilin, Nanning, Baoding, Tangshan, Zhengzhou
2025-03-25
Recruiting
Endovascular Treatment Beyond 24 Hours for Acute Ischemic Stroke Caused by Anterior Circulation Large Vessel Stenosis
NCT06959199Stroke, Cerebrovascular Disorders, Brain Diseases, Nervous System Diseases
The Second Hospital of Anhui Medical University
Not applicable
432
Hefei
2025-03-24
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 3
194
Hangzhou, Harbin, Hefei, Jinhua, Nanchang, Nantong, Shanghai, Ürümqi
2025-03-24
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
660
Bozhou, Hefei, Lu'an, Tongling, Beijing, Xiamen, Zhangzhou, Lanzhou
2025-03-21
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
383
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Liuzhou, Guiyang
2025-03-20
Not yet open
Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases
NCT06871644Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Not applicable
18
Hefei
2025-03-18
Active, closed
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
256
Hefei, Beijing, Chongqing, Foshan, Jiangmen, Liuzhou, Yulin, Cangzhou
2025-03-17
Recruiting
Efficacy and Safety of HN2301 in Autoimmune Diseases(AIDs)
NCT06801119Systemic Lupus Erythematosus, Scleroderma, Rheumatoid Arthritis
Shenzhen MagicRNA Biotechnology Co., Ltd
Phase 1
30
Hefei
2025-03-16
Active, closed
Anhui Provincial Cancer Hospital
Phase 1/2
28
Hefei
2025-03-13
Active, closed
Celgene
Phase 3
960
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Huizhou, Changzhou, Nanjing
2025-03-13
Recruiting
Efficacy and Safety of AK104 Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer
NCT06542549Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody), Chemotherapy, Efficacy
Anhui Provincial Hospital
Phase 3
100
Hefei
2025-03-11
Recruiting
Newly-diagnosed Pediatric T-cell ALL Protocol
NCT06855810Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
610
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2025-03-11
Recruiting
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
NCT06882057Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
3,000
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2025-03-03
Not yet open
Deep Sedation in Catheter Ablation of Atrial Fibrillation
NCT06836999Atrial Fibrillation, Atrial Fibrillation, Paroxysmal or Persistent, Deep Sedations, Conscious Sedation
The First Affiliated Hospital of Dalian Medical University
Not applicable
1,334
Hefei, Guangzhou, Nanjing, Suzhou, Nanchang, Dalian, Qingdao, Shanghai
2025-03-03
Recruiting
Anhui Medical University
Not applicable
60
Hefei
2025-03-01
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
120
Bengbu, Hefei, Beijing, Lanzhou, Guangzhou, Shenzhen, Nanning, Langfang
2025-03
Recruiting
Daiichi Sankyo
Phase 3
726
Beijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou
2025-02-27
Recruiting
Daiichi Sankyo
Observational
260
Beijing, Changchun, Changzhi, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei
2025-02-27
Recruiting
Anhui Provincial Cancer Hospital
Phase 2
56
Hefei
2025-02-25
Active, closed
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
203
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2025-02-24
Recruiting
Daiichi Sankyo
Observational
150
Beijing, Changsha, Fuzhou, Guangdong, Guangzhou, Hangzhou, Hebei, Hefei
2025-02-21
Recruiting
Dianthus Therapeutics
Phase 3
256
Hefei, Guangzhou, Changsha, Chifeng, Suzhou, Beijing, Chengdu, Fujian
2025-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Wuxi, Changchun, Beijing
2025-02-07
By invitation
Daunorubicin + Cytarabine + Venetoclax in de Novo AML
NCT06697327Leukemia, Myeloid, Acute, Acute Myeloid Leukemia
Anhui Medical University
Not applicable
94
Hefei
2025-02-01
Not yet open
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment
NCT06788626Acute Ischemic Stroke, Large Vessel Occlusion, Neuroprotective Drugs, Endovascular Treatment
Wei Hu
Phase 3
390
Hefei
2025-02
Not yet open
Evaluation of an Artificial Intelligence Model for the Prediction of Human Blastocyst Ploidy Without Invasive Procedures
NCT06762704The Focus is to Validate the Accuracy of a Non-invasive Artificial Intelligence Model for the Prediction of the Human Blastocyst Ploidy, Preimplantation Genetic Testing (PGT)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
1,408
Hefei, Nanjing, Nanchang, Xi'an, Shanghai
2025-02
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Hefei, Beijing, Guangzhou, Wuhan, Harbin, Changsha, Chengdu, Hangzhou
2025-01-29
Recruiting
Pfizer
Phase 3
211
Hefei, Nanchang, Shanghai, Kunming, Beijing
2025-01-22
Active, closed
argenx
Phase 3
631
Bengbu, Hefei, Guangzhou, Nanning, Guiyang, Shijiazhuang, Luoyang, Xinxiang
2025-01-15
Recruiting
BeOne Medicines
Phase 1
695
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou, Nanning
2025-01-10
Recruiting
Fortvita Biologics (USA)Inc.
Phase 1
250
Hefei, Beijing, Fuzhou, Nanning, Harbin, Anyang, Luoyang, Zhengzhou
2025-01-10
Recruiting
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 3
228
Bengbu, Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou
2025-01-10
Active, closed
TJ Biopharma Co., Ltd.
Phase 2
150
Beijing, Binzhou, Chengdu, Chongqing, Ha’erbin, Hefei, Jiangmen, Kunming
2025-01-09
Active, closed
Pfizer
Phase 3
1,035
Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Nanning, Harbin, Wuhan
2025-01-06
Recruiting
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
NCT06764238Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
1,800
Hefei, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha, Nanjing
2025-01-03
Recruiting
Anhui Provincial Hospital
Observational
10,000
Anqing, Bengbu, Bozhou, Chizhou, Chuzhou, Fuyang, Hefei, Huaibei
2025-01-01
By invitation
Study on Early Visual Dysfunction in Patients With Systemic Lupus Erythematosus
NCT07679776Systemic Lupus Erythematosus (SLE), Visual Function
The First Affiliated Hospital of Anhui Medical University
Observational
100
Hefei
2025-01-01
Recruiting
Anhui Provincial Hospital
Observational
70
Hefei
2025-01-01
Active, closed
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
258
Chuzhou, Hefei, Huainan, Beijing, Lanzhou, Foshan, Guangzhou, Jiangmen
2024-12-31
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
190
Hefei, Fuzhou, Zhengzhou, Changsha, Nanchang, Jinan, Hangzhou
2024-12-30
Recruiting
Anhui Provincial Hospital
Early Phase 1
30
Hefei
2024-12-19
Recruiting
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
NCT06656494Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
266
Hefei, Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Nanchang
2024-12-18
Recruiting
The First Affiliated Hospital of University of Science and Technology of China
Not applicable
360
Hefei
2024-12-16
Recruiting
Sinovac Biotech Co., Ltd
Phase 3
8,000
Hefei, Fujian, Guangdong, Hubei
2024-12-13
Recruiting
First Affiliated Hospital of Ningbo University
Not applicable
216
Harbin, Hefei, Jingzhou, Ningbo, Ninghai, Taizhou
2024-12-13
Recruiting
BeOne Medicines
Phase 1
168
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Nanning, Shijiazhuang, Harbin
2024-12-09
Recruiting
The Efficacy and Safety of Precision REpetitive Transcranial Magnetic Stimulation in Alleviating Motor Symptom in Parkinson's Disease
NCT06383247Parkinson Disease, Transcranial Magenetic Stimualtion, Supplementary Motor Area
Anhui Medical University
Not applicable
290
Hefei
2024-12-06
Recruiting
Anhui Provincial Hospital
Observational
600
Hefei, Wuhu
2024-12-01
Recruiting
Romiplostim N01 for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing UCBT
NCT06693791Platelet Recovery After Umbilical Cord Blood Transplantation
Anhui Provincial Hospital
Phase 2
34
Hefei
2024-12-01
Recruiting
YiLin Zhao
Observational
45
Hefei, Hangzhou
2024-12-01
Recruiting
Anhui Provincial Hospital
Phase 1
12
Hefei
2024-11-29
Recruiting
Lee's Pharmaceutical Limited
Phase 3
440
Hefei, Beijing, Wuhan, Changsha, Hangzhou
2024-11-28
Recruiting
Nuvation Bio Inc.
Phase 3
194
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Zhengzhou
2024-11-27
Active, closed
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis:BDLL Chinese Cohort
NCT06649721Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis
Huashan Hospital
Phase 3
120
Hefei, Beijing, Xiamen, Nanning, Liupanshui, Shijiazhuang, Harbin, Jiamusi
2024-11-27
Recruiting
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
NCT06668103Non-Small Cell Lung Cancer With EGFR Mutation
Abbisko Therapeutics Co, Ltd
Phase 2
54
Hefei, Harbin, Wuhan, Changchun, Shanghai
2024-11-25
Rows per page Showing 1–500 of 896
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/hefei

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 896 of those studies with a site in Hefei.

How many clinical trials are recruiting in Hefei?

537 of the 896 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 135 have not yet opened recruitment, 210 are active but closed to new participants, and 14 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hefei), 896 studies
PhaseStudiesRecruitingShare
Phase 328913832.3%
Phase 21378315.3%
Not applicable1278614.2%
Phase 1985710.9%
Observational966410.7%
Phase 1/271547.9%
Phase 428183.1%
Early Phase 125192.8%
Phase 2/325182.8%

Most active sponsors

Lead sponsors with the most studies (Hefei)
Lead sponsorStudiesRecruiting
Anhui Provincial Hospital5844
Merck Sharp & Dohme LLC3618
Anhui Medical University2914
AstraZeneca2614
Eli Lilly and Company2512
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2212
Pfizer1912
The Second Hospital of Anhui Medical University1711
Tianjin Medical University1717
Anhui Provincial Cancer Hospital158
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.